alanine has been researched along with Liver Neoplasms in 85 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC)." | 9.17 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. ( Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L, 2013) |
| "Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC)." | 9.17 | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. ( Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I, 2013) |
| "Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 8.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments." | 8.12 | Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. ( Jeong, S; Kim, HI; Shin, HP, 2022) |
| "Whether entecavir (ETV) or tenofovir alafenamide (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear." | 8.02 | Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 8.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "It is unclear whether tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is more effective for preventing hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB)." | 8.02 | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "The purpose of this article is to evaluate the antiangiogenic effects of brivanib using dynamic contrast-enhanced MRI (DCE-MRI) in an orthotopic mouse model of human hepatocellular carcinoma (HCC)." | 7.80 | Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma. ( Choi, D; Im, GH; Kim, JH; Lee, JH; Lee, WJ; Song, KD; Yang, J, 2014) |
| "Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development." | 5.62 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. ( Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH, 2021) |
| "Sorafenib was then initiated; however, disease progression was noted 3 months later." | 5.51 | Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report. ( Yang, X; Yi, C; Zhang, C; Zhu, H, 2019) |
| "Brivanib is a novel, orally available dual tyrosine kinase inhibitor that selectively targets the key angiogenesis receptors VEGF‑R2, FGF‑R1 and FGF‑R2." | 5.39 | Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using ¹H HR-MAS spectroscopy and histopathology. ( Choi, D; Hwang, JH; Im, GH; Kim, JH; Lee, JH; Namgung, M; Song, KD; Yang, J; Yoon, S, 2013) |
| "Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC)." | 5.17 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. ( Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L, 2013) |
| "Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC)." | 5.17 | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. ( Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I, 2013) |
| " This phase I study compared the pharmacokinetics of brivanib in patients with hepatocellular carcinoma (HCC) and varying levels of hepatic impairment with those with non-HCC malignancies and normal liver function." | 5.17 | The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. ( Castillo Ferrando, JR; El-Khoueiry, A; Fischer, BS; Kollia, G; Krishnamurthi, SS; Masson, E; Posey, JA; Syed, S; Walters, I, 2013) |
| "Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012) |
| "Extrahepatic glucose release was evaluated during the anhepatic phase of liver transplantation in 14 recipients for localized hepatocarcinoma with mild or absent cirrhosis, who received a bolus of [6,6-2H2]glucose and l-[3-13C]alanine or l-[1,2-13C2]glutamine to measure glucose kinetics and to prove whether gluconeogenesis occurred from alanine and glutamine." | 5.11 | Nonhepatic glucose production in humans. ( Ammatuna, M; Battezzati, A; Caumo, A; Coppa, J; Luzi, L; Martino, F; Matthews, DE; Mazzaferro, V; Regalia, E; Romito, R; Sereni, LP, 2004) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 4.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments." | 4.12 | Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. ( Jeong, S; Kim, HI; Shin, HP, 2022) |
| "It is unclear whether tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is more effective for preventing hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB)." | 4.02 | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "Whether entecavir (ETV) or tenofovir alafenamide (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear." | 4.02 | Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. ( Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY, 2021) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 4.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study." | 3.81 | Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. ( Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L, 2015) |
| "The purpose of this article is to evaluate the antiangiogenic effects of brivanib using dynamic contrast-enhanced MRI (DCE-MRI) in an orthotopic mouse model of human hepatocellular carcinoma (HCC)." | 3.80 | Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma. ( Choi, D; Im, GH; Kim, JH; Lee, JH; Lee, WJ; Song, KD; Yang, J, 2014) |
| " Following hyperpolarized [1-(13)C]pyruvate injections, pyruvate and its metabolic products, alanine and lactate, were observed in the liver of five rats with hepatocellular carcinoma and five healthy control rats." | 3.76 | T(2) relaxation times of (13)C metabolites in a rat hepatocellular carcinoma model measured in vivo using (13)C-MRS of hyperpolarized [1-(13)C]pyruvate. ( Butts Pauly, K; Hurd, R; King, R; Le Roux, P; Mayer, D; Pfefferbaum, A; Spielman, D; Tropp, J; Vasanawala, S; Yen, YF, 2010) |
| "Concerns have increased about the risk of fatal adverse events (FAEs) associated with molecular targeted agents (MTAs) in the treatment of advanced hepatocellular carcinoma (HCC)." | 2.58 | Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. ( Hu, Y; Li, X; Lou, L; Tu, J; Wan, J; Wu, S; Wu, Z, 2018) |
| "Treatment of advanced hepatocellular carcinoma (HCC) remains challenging, particularly with the limited systemic therapy options." | 2.52 | Systemic therapy of hepatocellular carcinoma: current and promising. ( Kalyan, A; Kulik, L; Nimeiri, H, 2015) |
| "Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis." | 1.72 | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. ( Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022) |
| "Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development." | 1.62 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. ( Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH, 2021) |
| "To evaluate the impact of chronic hepatitis B virus infection (CHB) treatment on risk of cirrhosis, liver-related outcomes, and death among a diverse CHB cohort with a large proportion of African Americans." | 1.62 | Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. ( Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ, 2021) |
| "The prediction of hepatocellular carcinoma (HCC) development during nucleotide/nucleoside analog (NA) therapy is clinically important in patients with chronic hepatitis B." | 1.56 | Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y, 2020) |
| "Sorafenib was then initiated; however, disease progression was noted 3 months later." | 1.51 | Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report. ( Yang, X; Yi, C; Zhang, C; Zhu, H, 2019) |
| "2D DIGE and MS analyses were used to reveal proteomic signatures resulting from Notch3 inhibition in HepG2 cells, combined with brivanib treatment." | 1.51 | Brivanib in combination with Notch3 silencing shows potent activity in tumour models. ( Baglioni, M; Bolondi, L; D'Errico, A; Giannone, FA; Giovannini, C; Gramantieri, L; Salzano, AM; Scaloni, A; Svegliati Baroni, G; Vasuri, F; Vitale, M; Zambrano, N, 2019) |
| "Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of liver fibrosis." | 1.40 | Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. ( Banini, BA; Kim, TH; Mikhail, DS; Moser, CD; Nakamura, I; Roberts, LR; Shaleh, HM; Thornburgh, SR; Walters, I; Yang, JD; Zakharia, K, 2014) |
| "We used cultured human hepatoma cells and evaluated static intracellular profiles of amino acids and in vivo kinetics of H2S biomarker formation." | 1.40 | Vitamin B-6 restriction reduces the production of hydrogen sulfide and its biomarkers by the transsulfuration pathway in cultured human hepatoma cells. ( Banerjee, R; Chi, YY; DeRatt, BN; Gregory, JF; Kabil, O; Ralat, MA, 2014) |
| "Brivanib is a novel, orally available dual tyrosine kinase inhibitor that selectively targets the key angiogenesis receptors VEGF‑R2, FGF‑R1 and FGF‑R2." | 1.39 | Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using ¹H HR-MAS spectroscopy and histopathology. ( Choi, D; Hwang, JH; Im, GH; Kim, JH; Lee, JH; Namgung, M; Song, KD; Yang, J; Yoon, S, 2013) |
| "Ixabepilone was more potent than doxorubicin." | 1.39 | In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. ( Chang, AY; Wang, M, 2013) |
| "The primary lesion of the carcinoid was probably the bronchus." | 1.32 | A novel missense mutation of the MEN1 gene in a multiple endocrine neoplasia type 1 patient associated with carcinoid syndrome. ( Nishikawa, M; Shigeta, H; Tanaka, T; Ukita, C; Yamaguchi, M, 2003) |
| "The human hepatoma cell line Hep G2 was used to investigate amino acid transport systems in human liver tissue." | 1.28 | Amino acid transport systems in the human hepatoma cell line Hep G2. ( Boutron, A; Goenner, S; Lemonnier, A; Moatti, N; Soni, T, 1992) |
| "1." | 1.26 | Influence of serum and insulin on the accumulation of aminoisobutyrate by rat hepatoma cells. ( Grimm, J; Manchester, KL, 1976) |
| "Alanosine treatment results in the inhibition of cell division, DNA synthesis, RNA and protein synthesis (in this order), and a depletion of the cells of adenosine triphosphate." | 1.26 | Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate. ( Graff, JC; Plagemann, PG, 1976) |
| "Other enzyme levels in the hepatoma tissue were as follows: Glucose-6-phosphatase, norma; fructose-1,6-bisphosphatase, reduced; glucokinase, absent; and hexokinase Types I and III, and glucose-6-phosphate dehydrogenase, slightly increased." | 1.26 | A case of minimal deviation hepatoma in man with elevated liver-type pyruvate kinase isozyme. ( Taketa, K; Ueda, M; Watanabe, A, 1977) |
| "In lung cancer tissue, the activity of aminopeptidase toward L-leucinamide was abnormally low, while the activity of arylamidase toward L-leucyl-beta-napthylamide was similar to that in normal lung." | 1.25 | Aminopeptidases and arylamidases in normal and cancer tissues in humans. ( Arima, T; Fujii, S; Niinobe, M; Okuda, H; Tamura, Y, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (29.41) | 18.7374 |
| 1990's | 3 (3.53) | 18.2507 |
| 2000's | 8 (9.41) | 29.6817 |
| 2010's | 34 (40.00) | 24.3611 |
| 2020's | 15 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, S | 1 |
| Shin, HP | 1 |
| Kim, HI | 1 |
| Chon, HY | 1 |
| Ahn, SH | 3 |
| Kim, YJ | 1 |
| Yoon, JH | 1 |
| Lee, JH | 4 |
| Sinn, DH | 1 |
| Kim, SU | 3 |
| Lim, J | 1 |
| Choi, WM | 1 |
| Shim, JH | 1 |
| Lee, D | 1 |
| Kim, KM | 1 |
| Lim, YS | 1 |
| Lee, HC | 1 |
| Choi, J | 1 |
| Hu, X | 1 |
| Li, R | 1 |
| Li, Q | 1 |
| Zang, M | 1 |
| Yuan, G | 1 |
| Chen, J | 1 |
| Abushawish, KYI | 1 |
| Soliman, SSM | 1 |
| Giddey, AD | 1 |
| Al-Hroub, HM | 1 |
| Mousa, M | 1 |
| Alzoubi, KH | 1 |
| El-Huneidi, W | 1 |
| Abu-Gharbieh, E | 1 |
| Omar, HA | 1 |
| Elgendy, SM | 1 |
| Bustanji, Y | 1 |
| Soares, NC | 1 |
| Semreen, MH | 1 |
| Wen, Q | 1 |
| Huang, M | 1 |
| Xie, J | 1 |
| Liu, R | 1 |
| Miao, Q | 1 |
| Huang, J | 1 |
| Zhang, J | 1 |
| Lyu, W | 1 |
| Qi, M | 1 |
| Wu, C | 2 |
| Qi, Q | 1 |
| Zhang, Z | 1 |
| Deng, R | 1 |
| Wang, C | 1 |
| Chen, ZS | 1 |
| Zhang, D | 1 |
| Ye, W | 1 |
| Chen, M | 1 |
| Liu, Z | 1 |
| Jin, D | 1 |
| Wei, X | 1 |
| Gao, Y | 1 |
| Gao, X | 1 |
| Li, X | 2 |
| Wang, X | 2 |
| Wei, P | 1 |
| Liu, T | 1 |
| Kirino, S | 1 |
| Tamaki, N | 1 |
| Kaneko, S | 1 |
| Kurosaki, M | 1 |
| Inada, K | 1 |
| Yamashita, K | 1 |
| Osawa, L | 1 |
| Hayakawa, Y | 1 |
| Sekiguchi, S | 1 |
| Watakabe, K | 1 |
| Okada, M | 1 |
| Wang, W | 1 |
| Shimizu, T | 1 |
| Higuchi, M | 1 |
| Takaura, K | 1 |
| Maeyashiki, C | 1 |
| Yasui, Y | 1 |
| Nakanishi, H | 1 |
| Tsuchiya, K | 1 |
| Itakura, J | 1 |
| Takahashi, Y | 1 |
| Izumi, N | 1 |
| Fei, Z | 1 |
| Lijuan, Y | 1 |
| Jing, Z | 1 |
| Xi, Y | 1 |
| Yuefen, P | 1 |
| Shuwen, H | 1 |
| Yip, TC | 2 |
| Wong, GL | 2 |
| Wong, RJ | 1 |
| Jain, MK | 1 |
| Therapondos, G | 1 |
| Niu, B | 1 |
| Kshirsagar, O | 1 |
| Thamer, M | 1 |
| Hui, VW | 1 |
| Wong, VW | 1 |
| Tse, YK | 1 |
| Chan, HL | 1 |
| Lui, GC | 1 |
| Naser, FJ | 1 |
| Jackstadt, MM | 1 |
| Fowle-Grider, R | 1 |
| Spalding, JL | 1 |
| Cho, K | 1 |
| Stancliffe, E | 1 |
| Doonan, SR | 1 |
| Kramer, ET | 1 |
| Yao, L | 1 |
| Krasnick, B | 1 |
| Ding, L | 1 |
| Fields, RC | 1 |
| Kaufman, CK | 1 |
| Shriver, LP | 1 |
| Johnson, SL | 1 |
| Patti, GJ | 1 |
| Lee, HW | 2 |
| Cho, YY | 2 |
| Lee, H | 2 |
| Lee, JS | 2 |
| Park, JY | 2 |
| Kim, DY | 2 |
| Kim, BK | 2 |
| Park, SY | 2 |
| Adachi, Y | 1 |
| De Sousa-Coelho, AL | 1 |
| Harata, I | 1 |
| Aoun, C | 1 |
| Weimer, S | 1 |
| Shi, X | 1 |
| Gonzalez Herrera, KN | 1 |
| Takahashi, H | 1 |
| Doherty, C | 1 |
| Noguchi, Y | 1 |
| Goodyear, LJ | 1 |
| Haigis, MC | 1 |
| Gerszten, RE | 1 |
| Patti, ME | 1 |
| Wan, J | 1 |
| Wu, Z | 1 |
| Tu, J | 1 |
| Hu, Y | 1 |
| Wu, S | 1 |
| Lou, L | 1 |
| Giovannini, C | 1 |
| Salzano, AM | 1 |
| Baglioni, M | 1 |
| Vitale, M | 1 |
| Scaloni, A | 1 |
| Zambrano, N | 1 |
| Giannone, FA | 1 |
| Vasuri, F | 1 |
| D'Errico, A | 1 |
| Svegliati Baroni, G | 1 |
| Bolondi, L | 1 |
| Gramantieri, L | 1 |
| Zhu, H | 1 |
| Zhang, C | 1 |
| Yang, X | 1 |
| Yi, C | 1 |
| Faitot, F | 1 |
| Ruhland, E | 1 |
| Oncioiu, C | 1 |
| Besch, C | 1 |
| Addeo, P | 1 |
| Cicek, AE | 1 |
| Bachellier, P | 1 |
| Namer, IJ | 1 |
| Swisher, CL | 1 |
| Larson, PE | 2 |
| Kruttwig, K | 1 |
| Kerr, AB | 1 |
| Hu, S | 2 |
| Bok, RA | 2 |
| Goga, A | 2 |
| Pauly, JM | 1 |
| Nelson, SJ | 2 |
| Kurhanewicz, J | 2 |
| Vigneron, DB | 2 |
| El-Khoueiry, A | 1 |
| Posey, JA | 1 |
| Castillo Ferrando, JR | 1 |
| Krishnamurthi, SS | 1 |
| Syed, S | 1 |
| Kollia, G | 1 |
| Walters, I | 7 |
| Fischer, BS | 1 |
| Masson, E | 1 |
| Johnson, PJ | 2 |
| Qin, S | 1 |
| Park, JW | 5 |
| Poon, RT | 3 |
| Raoul, JL | 4 |
| Philip, PA | 1 |
| Hsu, CH | 1 |
| Hu, TH | 1 |
| Heo, J | 1 |
| Xu, J | 1 |
| Lu, L | 2 |
| Chao, Y | 2 |
| Boucher, E | 2 |
| Han, KH | 1 |
| Paik, SW | 1 |
| Robles-Aviña, J | 1 |
| Kudo, M | 5 |
| Yan, L | 2 |
| Sobhonslidsuk, A | 1 |
| Komov, D | 1 |
| Decaens, T | 4 |
| Tak, WY | 3 |
| Jeng, LB | 1 |
| Liu, D | 2 |
| Ezzeddine, R | 2 |
| Cheng, AL | 1 |
| Kelley, RK | 1 |
| Llovet, JM | 4 |
| Chang, C | 2 |
| Kang, YK | 3 |
| Assenat, E | 2 |
| Lim, HY | 3 |
| Boige, V | 2 |
| Mathurin, P | 1 |
| Fartoux, L | 1 |
| Lin, DY | 1 |
| Bruix, J | 1 |
| Sherman, M | 1 |
| Blanc, JF | 2 |
| Finn, RS | 5 |
| Yang, J | 3 |
| Song, KD | 2 |
| Kim, JH | 2 |
| Im, GH | 2 |
| Yoon, S | 1 |
| Namgung, M | 1 |
| Hwang, JH | 1 |
| Choi, D | 2 |
| Darpolor, MM | 2 |
| Basu, SS | 1 |
| Worth, A | 1 |
| Nelson, DS | 1 |
| Clarke-Katzenberg, RH | 2 |
| Glickson, JD | 1 |
| Kaplan, DE | 1 |
| Blair, IA | 1 |
| Qi, X | 1 |
| Jia, J | 1 |
| Fan, D | 1 |
| Han, G | 2 |
| Nakamura, I | 1 |
| Zakharia, K | 1 |
| Banini, BA | 1 |
| Mikhail, DS | 1 |
| Kim, TH | 1 |
| Yang, JD | 1 |
| Moser, CD | 1 |
| Shaleh, HM | 1 |
| Thornburgh, SR | 1 |
| Roberts, LR | 1 |
| Nielsen, DL | 1 |
| Palshof, JA | 1 |
| Larsen, FO | 1 |
| Jensen, BV | 1 |
| Pfeiffer, P | 1 |
| Lee, WJ | 1 |
| Bolos, D | 1 |
| Yu, X | 1 |
| Lin, SM | 1 |
| Tanwandee, T | 1 |
| Shao, G | 1 |
| Walters, IB | 1 |
| Dela Cruz, C | 1 |
| Poulart, V | 1 |
| Wang, JH | 1 |
| DeRatt, BN | 1 |
| Ralat, MA | 1 |
| Kabil, O | 1 |
| Chi, YY | 1 |
| Banerjee, R | 1 |
| Gregory, JF | 1 |
| Kalyan, A | 1 |
| Nimeiri, H | 1 |
| Kulik, L | 1 |
| Nault, JC | 1 |
| Pigneur, F | 1 |
| Nelson, AC | 1 |
| Costentin, C | 1 |
| Tselikas, L | 1 |
| Katsahian, S | 1 |
| Diao, G | 1 |
| Laurent, A | 1 |
| Mallat, A | 1 |
| Duvoux, C | 1 |
| Luciani, A | 1 |
| Cabral de Melo, FC | 1 |
| Borsato, D | 1 |
| de Macedo Júnior, FC | 1 |
| Mantovani, MS | 1 |
| Luiz, RC | 1 |
| Colabone-Celligoi, MA | 1 |
| Lencioni, R | 1 |
| Montal, R | 1 |
| Torres, F | 1 |
| Ríos, J | 1 |
| Zhang, Q | 1 |
| Gao, J | 1 |
| Li, L | 1 |
| Chen, HB | 1 |
| Li, XQ | 1 |
| Yan, XZ | 1 |
| Nahon, P | 1 |
| Charnaux, N | 1 |
| Friand, V | 1 |
| Prost-Squarcioni, C | 1 |
| Ziol, M | 1 |
| Lièvre, N | 1 |
| Trinchet, JC | 1 |
| Beaugrand, M | 1 |
| Gattegno, L | 1 |
| Pessayre, D | 1 |
| Sutton, A | 1 |
| Huynh, H | 1 |
| Ngo, VC | 1 |
| Fargnoli, J | 1 |
| Ayers, M | 1 |
| Soo, KC | 1 |
| Koong, HN | 1 |
| Thng, CH | 1 |
| Ong, HS | 1 |
| Chung, A | 1 |
| Chow, P | 1 |
| Pollock, P | 1 |
| Byron, S | 1 |
| Tran, E | 1 |
| Yen, YF | 2 |
| Le Roux, P | 1 |
| Mayer, D | 2 |
| King, R | 1 |
| Spielman, D | 1 |
| Tropp, J | 1 |
| Butts Pauly, K | 1 |
| Pfefferbaum, A | 2 |
| Vasanawala, S | 1 |
| Hurd, R | 1 |
| Kim, JS | 1 |
| Karwal, M | 1 |
| Li, RK | 1 |
| Ismail, F | 1 |
| Thomas, M | 1 |
| Harris, R | 1 |
| Baudelet, C | 2 |
| Chua, MS | 1 |
| Xing, L | 1 |
| Shi, W | 1 |
| Josan, S | 1 |
| Hurd, RE | 1 |
| Senadheera, L | 1 |
| So, S | 1 |
| Hofmann, LV | 1 |
| Glazer, GM | 1 |
| Spielman, DM | 1 |
| Balakrishnan, A | 1 |
| Anderton, B | 1 |
| Schmitz, T | 1 |
| Blaickner, M | 1 |
| Ziegner, M | 1 |
| Bassler, N | 1 |
| Grunewald, C | 1 |
| Kratz, JV | 1 |
| Schütz, C | 1 |
| Langguth, P | 1 |
| Sharpe, P | 1 |
| Palmans, H | 1 |
| Holzscheiter, MH | 1 |
| Otto, G | 1 |
| Hampel, G | 1 |
| Mulcahy, M | 1 |
| Polite, BN | 1 |
| Manekas, D | 1 |
| Villanueva, A | 1 |
| Bayram, S | 1 |
| Chang, AY | 1 |
| Wang, M | 1 |
| Battezzati, A | 1 |
| Caumo, A | 1 |
| Martino, F | 1 |
| Sereni, LP | 1 |
| Coppa, J | 1 |
| Romito, R | 1 |
| Ammatuna, M | 1 |
| Regalia, E | 1 |
| Matthews, DE | 1 |
| Mazzaferro, V | 1 |
| Luzi, L | 1 |
| Penning, TM | 1 |
| Jin, Y | 1 |
| Heredia, VV | 1 |
| Lewis, M | 1 |
| RUTMAN, RJ | 1 |
| CANTAROW, A | 1 |
| PASCHKIS, KE | 1 |
| CAMPBELL, PN | 1 |
| HALLIDAY, JW | 1 |
| WAGLE, SR | 1 |
| MORRIS, HP | 2 |
| WEBER, G | 1 |
| ATCHLEY, WA | 1 |
| BHAGAVAN, NV | 1 |
| Ukita, C | 1 |
| Yamaguchi, M | 1 |
| Tanaka, T | 2 |
| Shigeta, H | 1 |
| Nishikawa, M | 1 |
| Proud, CG | 1 |
| Nishimura, A | 1 |
| Wasa, M | 1 |
| Bode, BP | 1 |
| Souba, WW | 1 |
| Nomura, H | 1 |
| Miyake, K | 1 |
| Hirakata, R | 1 |
| Migita, S | 1 |
| Okamoto, O | 1 |
| Shiraishi, G | 1 |
| Abe, K | 1 |
| Hirai, M | 1 |
| Mizuno, K | 1 |
| Higashi, N | 1 |
| Sekimoto, T | 1 |
| Miki, T | 1 |
| Hirano, T | 1 |
| Nakajima, K | 1 |
| Grimm, J | 1 |
| Manchester, KL | 1 |
| Brummel, MC | 1 |
| Carlotti, RJ | 1 |
| Stegink, LD | 1 |
| Shepherd, JA | 1 |
| Vestling, CS | 1 |
| Irving, MG | 1 |
| Williams, JF | 1 |
| Graff, JC | 1 |
| Plagemann, PG | 1 |
| Taketa, K | 1 |
| Ueda, M | 1 |
| Watanabe, A | 1 |
| Bornschein, W | 1 |
| Plovnick, H | 1 |
| Ruderman, NB | 1 |
| Aoki, T | 1 |
| Chideckel, EW | 1 |
| Poffenbarger, PL | 1 |
| Tamura, Y | 1 |
| Niinobe, M | 1 |
| Arima, T | 1 |
| Okuda, H | 1 |
| Fujii, S | 1 |
| Goenner, S | 1 |
| Boutron, A | 1 |
| Soni, T | 1 |
| Lemonnier, A | 1 |
| Moatti, N | 1 |
| Umezawa, I | 1 |
| Funayama, S | 1 |
| Okada, K | 1 |
| Iwasaki, K | 1 |
| Satoh, J | 1 |
| Masuda, K | 1 |
| Komiyama, K | 1 |
| Liaw, KY | 1 |
| Tsang, YM | 1 |
| Su, CT | 1 |
| Chang, CN | 1 |
| Liu, JL | 1 |
| Wei, TC | 1 |
| Lin, JK | 1 |
| Dybing, E | 2 |
| Byvoet, P | 2 |
| Mulay, AS | 1 |
| O'Gara, RW | 1 |
| Imamura, K | 1 |
| Taniuchi, K | 1 |
| Mercier, J | 1 |
| Befort, N | 1 |
| Beck, JP | 1 |
| Ebel, JP | 1 |
| Rugstad, HE | 1 |
| Bratlid, D | 1 |
| Peters, JE | 1 |
| Nilius, R | 1 |
| Otto, L | 1 |
| Schlaeger, R | 1 |
| Kattermann, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmacokinetic Study of Brivanib (BMS-582664) in Subjects With Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma With Impaired Hepatic Function[NCT00437424] | Phase 1 | 24 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma[NCT00858871] | Phase 3 | 1,714 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Briva[NCT00825955] | Phase 3 | 587 participants (Actual) | Interventional | 2009-02-17 | Completed | ||
| A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regim[NCT00355238] | Phase 2 | 137 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
FHSI-8 (Functional Assessment of Cancer Therapy, Hepatobiliary, Symptom Index) was used to assess HCC-related symptoms. The FHSI-8 includes eight items representing HCC-related symptoms; each symptom is rated by participants on a scale of from 0 to 4. The FHSI-8 total score ranges in value from 0 to 32, with higher scores representing fewer symptoms and lower scores representing more symptoms. (NCT00355238)
Timeframe: Baseline and end of treatment (up to approximately 33 months)
| Intervention | Change from baseline in FSHI-8 score (Mean) |
|---|---|
| Group A (Brivanib 800 mg QD) | -4.01 |
| Group B (Brivanib 800 mg QD) | -2.40 |
| Group C (400 mg BID) | -1.06 |
"The percent of participants whose best response is a partial response (PR), complete response (CR) or stable disease (SD).~Complete Response (CR): Disappearance of all known disease. Must be confirmed 4 or more weeks later.~Partial Response (PR): A 50% or more decrease in the sum of all index lesion areas compared to the baseline sum and no unequivocal progression of existing non-index lesions. In addition, there can be no appearance of new lesions. Must be confirmed 4 or more weeks later.~Stable Disease (SD): A decrease of 50% or more or an increase of 25% or more in the sum of all index lesion areas compared to baseline cannot be established. There can be no appearance of new lesions. Documentation must occur 6 weeks (42 days) or more from the baseline determination." (NCT00355238)
Timeframe: From first dose to the date of the first documented response (up to approximately 34 months)
| Intervention | Percent of participants (Number) |
|---|---|
| Group A (Brivanib 800 mg QD) | 50.9 |
| Group B (Brivanib 800 mg QD) | 45.7 |
| Group C (400 mg BID) | 54.5 |
"Duration of response will be computed as from time measurement criteria are met for PR or CR until the date of documented progressive disease or death. Participants who neither relapse nor die will be censored on the date of their last tumor assessment. Progression is defined as a 25% or more increase in the sum of all index lesion areas taking as reference the smallest sum recorded at or following baseline.~Complete Response (CR): Disappearance of all known disease. Must be confirmed 4 or more weeks later.~Partial Response (PR): A 50% or more decrease in the sum of all index lesion areas compared to the baseline sum and no unequivocal progression of existing non-index lesions. In addition, there can be no appearance of new lesions. Must be confirmed 4 or more weeks later." (NCT00355238)
Timeframe: From first dose to the date of documented progressive disease or death (up to approximately 34 months)
| Intervention | Months (Median) |
|---|---|
| Group A (Brivanib 800 mg QD) | 2.9 |
| Group B (Brivanib 800 mg QD) | 4.2 |
The time (in months) from first dosing until the date of death. For those participants who have not died, survival duration will be censored at the last date the participant was known to be alive. (NCT00355238)
Timeframe: From first dose to the date of death (up to approximately 34 months)
| Intervention | Months (Median) |
|---|---|
| Group A (Brivanib 800 mg QD) | 9.95 |
The time (in months) from first dosing until the date of death. For those participants who have not died, survival duration will be censored at the last date the participant was known to be alive. (NCT00355238)
Timeframe: From first dose to the date of death (up to approximately 34 months)
| Intervention | Months (Median) |
|---|---|
| Group B (Brivanib 800 mg QD) | 9.79 |
| Group C (400 mg BID) | 8.25 |
"The time (in months) from first dosing date to the date of progression per IRRC. Participants who die without a reported prior progression will be considered to have progressed on their date of death (as found in the BMS clinical database). Participants who did not progress or die will be censored on the date of their last tumor assessment. Participants who have only baseline tumor assessment will be censored on the first dosing date.~Progression is defined as a 25% or more increase in the sum of all index lesion areas taking as reference the smallest sum recorded at or following baseline." (NCT00355238)
Timeframe: From first dose to the date of the first documented progression (up to approximately 34 months)
| Intervention | Months (Median) |
|---|---|
| Group A (Brivanib 800 mg QD) | 2.69 |
| Group B (Brivanib 800 mg QD) | 2.0 |
| Group C (400 mg BID) | 2.96 |
"The percent of participants who have not progressed or died prior to 6 months from the date of their first dose. Participants who have neither progressed nor died but had their last tumor assessment prior to 6 months will not be categorized as progression free and will not be included. Tumor response was measured by the IRRC using mWHO criteria.~Progression is defined as a 25% or more increase in the sum of all index lesion areas taking as reference the smallest sum recorded at or following baseline." (NCT00355238)
Timeframe: From first dose up to approximately 6 months after first dose
| Intervention | Percent of participants (Number) |
|---|---|
| Group A (Brivanib 800 mg QD) | 22.4 |
An Adverse Event (AE) is defined as any new untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. (NCT00355238)
Timeframe: From first dose up to 30 days post last dose (up to approximately 34 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Brivanib 800 mg QD) | 54 |
| Group B (Brivanib 800 mg QD) | 46 |
| Group C (400 mg BID) | 22 |
"The time from the first dose of study therapy until measurement criteria are first met for Partial response (PR) or complete response (CR), whichever is recorded first.~Complete Response (CR): Disappearance of all known disease. Must be confirmed 4 or more weeks later.~Partial Response (PR): A 50% or more decrease in the sum of all index lesion areas compared to the baseline sum and no unequivocal progression of existing non-index lesions. In addition, there can be no appearance of new lesions. Must be confirmed 4 or more weeks later." (NCT00355238)
Timeframe: From first dose to the date of the first documented response (up to approximately 34 months)
| Intervention | Months (Median) |
|---|---|
| Group A (Brivanib 800 mg QD) | 10.4 |
| Group B (Brivanib 800 mg QD) | 1.4 |
"The percent of participants whose best overall response is a partial response (PR) or complete response (CR). Tumor measurements by CT/ MRI of the chest, abdomen and pelvis will be obtained at pre-treatment (within 28 days prior to the start of treatment) and every 6 weeks.~Complete Response (CR): Disappearance of all known disease. Must be confirmed 4 or more weeks later.~Partial Response (PR): A 50% or more decrease in the sum of all index lesion areas compared to the baseline sum and no unequivocal progression of existing non-index lesions. In addition, there can be no appearance of new lesions. Must be confirmed 4 or more weeks later." (NCT00355238)
Timeframe: From first dose to the date of the first documented response (up to approximately 34 months)
| Intervention | Percent of participants (Number) |
|---|---|
| Group A (Brivanib 800 mg QD) | 7.3 |
| Group B (Brivanib 800 mg QD) | 4.3 |
| Group C (400 mg BID) | 0.0 |
5 reviews available for alanine and Liver Neoplasms
| Article | Year |
|---|---|
Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Topics: Aged; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Age | 2018 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2014 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Topics: Alanine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Tar | 2011 |
Structure-function relationships in 3alpha-hydroxysteroid dehydrogenases: a comparison of the rat and human isoforms.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific); 3-Hydroxysteroi | 2003 |
9 trials available for alanine and Liver Neoplasms
| Article | Year |
|---|---|
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
Topics: Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; | 2013 |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Fol | 2013 |
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resist | 2013 |
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2014 |
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellula | 2017 |
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-F | 2011 |
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alanine; alpha-Fetoproteins; Appetite; Carcino | 2012 |
Nonhepatic glucose production in humans.
Topics: Adult; Alanine; Blood Glucose; Carcinoma; Follow-Up Studies; Gluconeogenesis; Glutamine; Hepatectomy | 2004 |
Rebamipide prevents occurrence of gastric lesions following transcatheter arterial embolization in the hepatic artery.
Topics: Adult; Aged; Alanine; Carcinoma, Hepatocellular; Embolization, Therapeutic; Esophageal and Gastric V | 1999 |
71 other studies available for alanine and Liver Neoplasms
| Article | Year |
|---|---|
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chron | 2021 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; | 2022 |
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepati | 2022 |
Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.
Topics: Alanine; Amino Acids; Antineoplastic Agents; Biomarkers; Calpain; Carcinoma, Hepatocellular; Cell Li | 2022 |
lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2.
Topics: Alanine; Carrier Proteins; Cell Line, Tumor; Cysteine; Humans; In Situ Hybridization, Fluorescence; | 2023 |
ZBTB34 is a hepatocellular carcinoma-associated protein with a monopartite nuclear localization signal.
Topics: Alanine; Carcinoma, Hepatocellular; Humans; Karyopherins; Liver Neoplasms; Lysine; MicroRNAs; Nuclea | 2023 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; | 2020 |
Molecular characteristics associated with ferroptosis in hepatocellular carcinoma progression.
Topics: Activating Transcription Factor 3; Alanine; Carcinoma, Hepatocellular; Disease Progression; Ferropto | 2021 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B | 2020 |
Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
Topics: Adult; Aged; Alanine; Antiviral Agents; Asian; Black or African American; Carcinoma, Hepatocellular; | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combinatio | 2021 |
Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver.
Topics: Aging; Alanine; Animals; Animals, Genetically Modified; Cell Tracking; Disease Models, Animal; Gluco | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N | 2021 |
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; | 2021 |
l-Alanine activates hepatic AMP-activated protein kinase and modulates systemic glucose metabolism.
Topics: Adenosine Triphosphate; Alanine; Amino Acids; AMP-Activated Protein Kinases; Animals; Carbohydrate M | 2018 |
Brivanib in combination with Notch3 silencing shows potent activity in tumour models.
Topics: Alanine; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Electropho | 2019 |
Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
Topics: Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Age | 2019 |
Metabolomic profiling highlights the metabolic bases of acute-on-chronic and post-hepatectomy liver failure.
Topics: Acute-On-Chronic Liver Failure; Aged; Alanine; Biomarkers; Carcinoma, Hepatocellular; Female; Follow | 2019 |
Quantitative measurement of cancer metabolism using stimulated echo hyperpolarized carbon-13 MRS.
Topics: Alanine; Algorithms; Animals; Biomarkers, Tumor; Carbon Isotopes; Computer Simulation; Lactic Acid; | 2014 |
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, | 2013 |
Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using ¹H HR-MAS spectroscopy and histopathology.
Topics: Alanine; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Immunoenzyme Tec | 2013 |
The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Aspartic Acid; Carbon Isotopes; Carcinoma, Hepatocellular; | 2014 |
Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
Topics: Alanine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male | 2014 |
Reply to X. Qi et al.
Topics: Alanine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male | 2014 |
Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
Topics: Alanine; Animals; Carbon Tetrachloride Poisoning; Cell Line; Cell Proliferation; Cell Survival; Coll | 2014 |
Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Topics: Administration, Oral; Alanine; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Contrast | 2014 |
Systemic therapy in HCC: lessons from brivanib.
Topics: Alanine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male | 2014 |
Vitamin B-6 restriction reduces the production of hydrogen sulfide and its biomarkers by the transsulfuration pathway in cultured human hepatoma cells.
Topics: Alanine; Biomarkers; Carcinoma, Hepatocellular; Cysteine; Hep G2 Cells; Homocysteine; Humans; Hydrog | 2014 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Hu | 2015 |
Study of levan productivity from Bacillus subtilis Natto by surface response methodology and its antitumor activity against HepG2 cells using metabolomic approach.
Topics: Acetic Acid; Alanine; Antineoplastic Agents; Bacillus subtilis; Energy Metabolism; Fermentation; Fru | 2015 |
[Metabonomic study of blood plasma in the assessment of liver graft function].
Topics: Acetone; Alanine; Biomarkers; Blood Glucose; Carcinoma; Choline; Glutamine; Humans; Lactic Acid; Liv | 2007 |
The manganese superoxide dismutase Ala16Val dimorphism modulates iron accumulation in human hepatoma cells.
Topics: Alanine; Alcoholism; Alleles; Carcinoma, Hepatocellular; Cell Line; Frataxin; Genotype; Homeostasis; | 2008 |
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Topics: Alanine; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans | 2008 |
T(2) relaxation times of (13)C metabolites in a rat hepatocellular carcinoma model measured in vivo using (13)C-MRS of hyperpolarized [1-(13)C]pyruvate.
Topics: Alanine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Disease Models, Animal; Liver Neoplasm | 2010 |
In vivo MRSI of hyperpolarized [1-(13)C]pyruvate metabolism in rat hepatocellular carcinoma.
Topics: Alanine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic | 2011 |
13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression.
Topics: Alanine; Animals; Carbon Isotopes; Citric Acid Cycle; Disease Models, Animal; Gene Expression Profil | 2011 |
Dose determination using alanine detectors in a mixed neutron and gamma field for boron neutron capture therapy of liver malignancies.
Topics: Alanine; Boron Neutron Capture Therapy; Dose-Response Relationship, Radiation; Gamma Rays; Humans; L | 2011 |
Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
Topics: Alanine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Triazines | 2012 |
RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population.
Topics: Aged; Alanine; Amino Acid Substitution; Carcinoma, Hepatocellular; Case-Control Studies; Female; Gen | 2012 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2013 |
Studies in 2-acetylaminofluorene carcinogenesis. II. The in vitro uptake of alanine-1-C14 by preneoplastic liver and hepatoma mitochondrial protein.
Topics: 2-Acetylaminofluorene; Alanine; Carcinogenesis; Carcinoma, Hepatocellular; Fluorenes; In Vitro Techn | 1954 |
The conversion of glucose into alanine and glutamic acid by rat liver, liver tumour and kidney in vivo.
Topics: Alanine; Animals; Glucose; Glutamates; Glutamic Acid; Kidney; Liver Neoplasms; Rats | 1957 |
COMPARATIVE BIOCHEMISTRY OF HEPATOMAS. V. STUDIES ON AMINO ACID INCORPORATION IN LIVER TUMORS OF DIFFERENT GROWTH RATES.
Topics: Alanine; Amino Acids; Aspartic Acid; Carcinoma, Hepatocellular; Glycine; Histocytochemistry; Isoleuc | 1963 |
SALINE-SOLUBLE PREPARATIONS OF DEOXYRIBONUCLEOPROTEINS.
Topics: Acetates; Alanine; Aminobutyrates; Aminocaproates; Aminocaproic Acid; Animals; Cadmium; Caprylates; | 1964 |
A novel missense mutation of the MEN1 gene in a multiple endocrine neoplasia type 1 patient associated with carcinoid syndrome.
Topics: Alanine; Carcinoid Tumor; DNA Mutational Analysis; Duodenal Neoplasms; Female; Fluorescence; Humans; | 2003 |
A novel mechanism for the control of translation initiation by amino acids, mediated by phosphorylation of eukaryotic initiation factor 2B.
Topics: Alanine; Amino Acid Substitution; Amino Acids; Animals; Carcinoma, Hepatocellular; Catalytic Domain; | 2008 |
[Studies on hepatic gluconeogenesis in chronic liver diseases; with special references to the effects of L-alanine administration].
Topics: Alanine; Carcinoma, Hepatocellular; Chronic Disease; Gluconeogenesis; Hepatitis, Chronic; Humans; Li | 1984 |
Adaptive regulation of amino acid transport in nutrient-deprived human hepatomas.
Topics: Adaptation, Physiological; Alanine; Amino Acids; Arginine; Biological Transport; Carcinoma, Hepatoce | 1996 |
The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3T3 Cells; Alanine; Amino Acid Sequence; Amino Acid S | 2001 |
Influence of serum and insulin on the accumulation of aminoisobutyrate by rat hepatoma cells.
Topics: Alanine; Aminoisobutyric Acids; Animals; Blood; Carcinoma, Hepatocellular; Cycloheximide; Dactinomyc | 1976 |
Amino- and carboxyl-terminal analyses of hepatoma lactate dehydrogenase isozymes.
Topics: Alanine; Animals; Carcinoma, Hepatocellular; Isoenzymes; L-Lactate Dehydrogenase; Liver; Liver Neopl | 1975 |
Kinetic properties of pyruvate kinase isolated from rat hepatic tumours.
Topics: Adenosine Triphosphate; Alanine; Animals; Carcinoma, Hepatocellular; Diethylnitrosamine; Kinetics; L | 1976 |
Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate.
Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Alanine; Aspartic Acid; Carcinoma, Hepatoc | 1976 |
A case of minimal deviation hepatoma in man with elevated liver-type pyruvate kinase isozyme.
Topics: Alanine; Carcinoma, Hepatocellular; Electrophoresis; Fructose-Bisphosphatase; Glucose-6-Phosphatase; | 1977 |
[Isoenzymes of alaninarylamidase and gamma-glutamyl-transpeptidase in intrahepatic and extra-hepatic cholostasis (author's transl)].
Topics: Alanine; Bile Duct Neoplasms; Cholestasis; Diagnosis, Differential; Electrophoresis, Agar Gel; gamma | 1975 |
Non-beta-cell tumor hypoglycemia associated with increased nonsuppressible insulin-like protein (NSILP).
Topics: Aged; Alanine; Amino Acids; Blood Glucose; Fasting; Female; Glucagon; Humans; Hypoglycemia; Insulin; | 1979 |
Aminopeptidases and arylamidases in normal and cancer tissues in humans.
Topics: Alanine; Amides; Aminopeptidases; Colon; Digestive System; Humans; Ileum; Kidney; Leucine; Liver; Li | 1975 |
Amino acid transport systems in the human hepatoma cell line Hep G2.
Topics: Alanine; Amino Acids; Biological Transport; Carcinoma, Hepatocellular; Humans; Kinetics; Lithium; Li | 1992 |
Studies on a novel cytocidal antibiotic, trienomycin A. Taxonomy, fermentation, isolation, and physico-chemical and biological characteristics.
Topics: Alanine; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Cell Line; Chemical Phenomena; Chem | 1985 |
Studies on regional hepatic blood flow and substrate metabolism in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Alanine; Carcinoma, Hepatocellular; Fatty Acids, Nonesterified; Female; Glucose; Humans | 1986 |
Effects of membrane stabilizers on glucuronidation and amino acid transport in cultures of rat hepatoma cells.
Topics: Alanine; Aminoisobutyric Acids; Animals; Antipsychotic Agents; Biological Transport; Carcinoma, Hepa | 1973 |
Differences in turnover between histones and their acetyl N-terminal groups.
Topics: Acetates; Alanine; Animals; Carbon Isotopes; Carcinoma 256, Walker; Carcinoma, Hepatocellular; DNA; | 1968 |
N-acetylation of arginine-rich hepatoma histones.
Topics: Acetates; Alanine; Animals; Arginine; Carbon Isotopes; Carcinoma, Hepatocellular; Half-Life; Histone | 1971 |
Effect of diet on N,N-dimethyl-p-(m-tolylazo)aniline carcinogenesis in rats.
Topics: Alanine; Animals; Carcinoma, Hepatocellular; Diet; Female; Liver; Liver Neoplasms; Male; Neoplasm Me | 1971 |
Multimolecular forms of pyruvate kinase. II. Purification of M 2 -type pyruvate kinase from Yoshida ascites hepatoma 130 cells and comparative studies on the enzymological and immunological properties of the three types of pyruvate kinases, L, M 1 , and M
Topics: Adenosine Triphosphate; Alanine; Animals; Carcinoma, Hepatocellular; Chloromercuribenzoates; Female; | 1972 |
[Comparative study of transfer ribonucleic acids extracted from rat liver and Zajdela hepatoma. I. Study of the acceptor properties of tRNA].
Topics: Acylation; Alanine; Animals; Arginine; Ascites; Carcinoma, Hepatocellular; Cell Differentiation; Cel | 1972 |
Inhibitory effects of chlorpromazine and diethylaminoethyl diphenylvalerate (SKF 525-A) on alanine incorporation into protein and -aminoisobutyric acid uptake in rat hepatoma cells in culture.
Topics: Alanine; Aminobutyrates; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Cells, Cultured; Chlor | 1973 |
The effect of sulisoxazole (Gantrisin) and albumin on bilirubin conjugation in cultures of a clonal cell line with liver-like functions.
Topics: Alanine; Animals; Bilirubin; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Line; Cells, Cult | 1974 |
[Electrophoretic variants of alanine aminopeptidase in serum of patients with hepatobiliary diseases].
Topics: Alanine; Aminopeptidases; Biliary Tract Diseases; Electrophoresis; Gallbladder Diseases; Hepatitis; | 1973 |
[Arylamidase and its isoenzymes in diseases of the pancreas and liver].
Topics: Acute Disease; Agar; Alanine; Alkaline Phosphatase; Amides; Aminohydrolases; Anilides; Cholestasis; | 1971 |